FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 28, 2022

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Philip Bautista, PharmD, MPH

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Christopher H. Lieu, MD

(Acting Chairperson) Associate Professor of Medicine Associate Director for Clinical Research co-Director, Gastrointestinal Medical Oncology University of Colorado Cancer Center Aurora, Colorado

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine Section Head, Solid Tumors University of Southern California (USC) Norris Comprehensive Cancer Center Keck School of Medicine of USC Los Angeles, California

David E. Mitchell

(Consumer Representative) Founder, Patients for Affordable Drugs Bethesda, Maryland

Neil Vasan, MD, PhD

Assistant Professor Division of Hematology & Oncology Department of Medicine Herbert Irving Comprehensive Cancer Center Columbia University Medical Center New York, New York

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative) Head of Oncology Development Global Drug Development Bristol-Myers Squibb Lawrenceville, New Jersey

TEMPORARY MEMBERS (Voting)

Rochelle Bagatell, MD

Professor of Pediatrics Division of Oncology, Department of Pediatrics The Children's Hospital of Philadelphia University of Pennsylvania Philadelphia, Pennsylvania

<u>Natia Esiashvili, MD</u>

Professor Department of Radiation Oncology Winship Cancer Institute Emory University Atlanta, Georgia

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 28, 2022

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

David Harrington, MA, PhD

Professor of Biostatistics (Emeritus) Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health Boston, Massachusetts

Michele Jonsson Funk, PhD, FISPE

Associate Professor of Epidemiology Director, Center for Pharmacoepidemiology Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill, North Carolina

Tobey J. MacDonald, MD

Aflac Endowed Chair for Pediatric Neuro-Oncology Professor of Pediatrics Director, Pediatric Neuro-Oncology Program Aflac Cancer & Blood Disorders Center Children's Healthcare of Atlanta Emory University School of Medicine Atlanta, Georgia

<u>Julie R. Park, MD</u>

Professor of Pediatrics Division Pediatric Hematology Oncology University of Washington School of Medicine Seattle Children's Hospital Seattle, Washington

Michael Hudgens, PhD

Professor and Associate Chair Department of Biostatistics Gillings School of Global Public Health University of North Carolina at Chapel Hill Chapel Hill, North Carolina

E. Anders Kolb, MD

Director, Nemours Center for Cancer and Blood Disorders Nemours Children's Health Wilmington, Delaware Professor, Department of Pediatrics Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, Pennsylvania

Gianna (Gigi) McMillan, D.Bioethics

(Patient Representative) Professor of Research Ethics, Graduate Division Associate Director, Bioethics Institute Loyola Marymount University Los Angeles, California

Donald (Will) Parsons, MD, PhD

Sidney L. and Donald F. Faust Chair of Pediatric Cancer Precision Medicine Texas Children's Hospital Deputy Director, Texas Children's Cancer and Hematology Center Associate Professor, Department of Pediatrics, Section of Hematology-Oncology Baylor College of Medicine Houston, Texas

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting October 28, 2022

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting) (cont.)

<u>Nita Seibel, MD</u>

Head, Pediatric Solid Tumor Therapeutics Clinical Investigations Branch Cancer Therapy Evaluation Program Division of Cancer Treatment and Diagnosis National Cancer Institute (NCI) National Institutes of Health (NIH) Bethesda, Maryland

FDA PARTICIPANTS (Non-Voting)

<u>Richard Pazdur, MD</u>

Director, Oncology Center of Excellence (OCE) Director (Acting) Office of Oncologic Diseases (OOD) Office of New Drugs (OND), CDER, FDA

Gregory Reaman, MD

Associate Director for Pediatric Oncology, OCE Associate Director for Pediatric Oncology OOD, OND, CDER, FDA

Martha Donoghue, MD

Acting Associate Director for Pediatric and Rare Cancer Drug Development, OCE Deputy Director DO2, OOD, OND, CDER, FDA

Amy Barone, MD

Cross-Disciplinary Team Leader DO2, OOD, OND, CDER, FDA

Somak Chatterjee

Visiting Associate Division of Biometrics V Office of Biostatistics Office of Translational Sciences, CDER, FDA

Brigette Widemann, MD

Chief, Pediatric Oncology Branch Center for Cancer Research NCI, NIH Bethesda, Maryland

<u>Paul Kleutz, MD</u>

Deputy Director, OCE OOD, OND, CDER, FDA

Harpreet Singh, MD

Director Division of Oncology 2 (DO2) OOD, OND, CDER, FDA

Donna Rivera, PharmD, MSc

Associate Director for Pharmacoepidemiology OCE, FDA

Gautam Mehta, MD

Clinical Reviewer, Nervous System, Pediatrics and Rare Cancers DO2, OOD, OND, CDER, FDA